Balance Sheet StrengthA robust equity position and low leverage provide durable financial flexibility: the company can fund working capital, absorb demand shocks, and pursue selective R&D or small M&A without immediate refinancing. This structural strength supports long-term operational continuity.

Recent Revenue RecoveryA recent ~16.8% reported revenue increase signals a recovery in underlying demand and distribution execution. If sustained, this growth can expand scale economics, support higher fixed-cost absorption, and provide runway to restore profit margins over the coming 2–6 months.

Diversified Healthcare Revenue ModelRevenue streams across OTC consumer brands, prescription drugs, and other healthcare products create multi-channel stability. Consumer brand strength plus medical-channel sales reduce single-channel risk and support recurring revenue from pharmacies, drugstores and healthcare providers.

Bears Say

Declining ProfitabilityFalling net income and a negative EBIT margin indicate persistent operating weakness. Sustained margin compression erodes returns on capital, limits reinvestment into products and marketing, and reduces the firm’s ability to sustainably fund growth initiatives or raise ROE.

Weak Cash ConversionNegative operating and free cash flow show inefficiency converting reported earnings into cash. This structural cash gap can force reliance on external financing or asset sales, constrain investment, and heighten vulnerability to demand disruptions over the medium term.

Liquidity/Operating Efficiency IssuesCombined profitability decline and cash management shortfalls point to operating inefficiencies. Even with low leverage, liquidity pressures can limit operational agility, hamper timely supplier or channel investments, and necessitate strategic changes to restore sustainable margins.

4512 FAQ

What was Wakamoto Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Wakamoto Pharmaceutical Co., Ltd. lowest stock price was ¥270.00 and its highest was ¥371.00 in the past 12 months.

What is Wakamoto Pharmaceutical Co., Ltd.’s market cap?

Wakamoto Pharmaceutical Co., Ltd.’s market cap is ¥11.38B.

When is Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date is May 18, 2026 which is in 69 days.

How were Wakamoto Pharmaceutical Co., Ltd.’s earnings last quarter?

Wakamoto Pharmaceutical Co., Ltd. released its earnings results on Feb 04, 2026. The company reported ¥10.05 earnings per share for the quarter, beating the consensus estimate of N/A by ¥10.05.

Is Wakamoto Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Wakamoto Pharmaceutical Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Wakamoto Pharmaceutical Co., Ltd. pay dividends?

Wakamoto Pharmaceutical Co., Ltd. pays a Annually dividend of ¥3 which represents an annual dividend yield of 1.06%. See more information on Wakamoto Pharmaceutical Co., Ltd. dividends here

What is Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate?

Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Wakamoto Pharmaceutical Co., Ltd. have?

Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding.

What happened to Wakamoto Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Wakamoto Pharmaceutical Co., Ltd. reported an EPS of ¥10.05 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Wakamoto Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4512

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Wakamoto Pharmaceutical Co., Ltd.

Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.